



# Intravascular Imaging-Guided PCI: A Universal Approach for Optimization of Stent Implantation

# *Gary S. Mintz, MD*

# ***Cardiovascular Research Foundation***



# OCT vs IVUS vs QCA in Coronary Lesions and Phantoms





- IVUS-MLD - OCT-MLD = 0.18 mm
- QCA-MLD - OCT-MLD = -0.10 mm
- IVUS-MLA - OCT-MLA was significantly greater in non-stented vs stented segments (0.56 mm<sup>2</sup> vs. 0.25 mm<sup>2</sup>; p<0.007).

- IVUS-MLA - OCT-MLA was significantly greater in non-stented vs stented segments (11.3% vs. 2.7%).



# In vivo comparison of OCT vs HD-IVUS

- Pre-intervention . . .
  - no significant differences regarding proximal and distal reference lumen areas as well as in the assessment of MLA or lesion length.
  - Some lipid-predominant lesions on OCT were classified as fibrotic with HD-IVUS
  - OCT more frequently revealed the presence of plaque rupture or intraluminal thrombus
  - HD-IVUS enabled better visualization of the external elastic membrane
- Post-intervention . . .
  - HD-IVUS was comparable to OCT in the estimation of MSA
  - OCT more frequently detected the presence of tissue protrusion as well as both the number and percentage of malapposed struts
  - OCT more frequently identified the presence of stent-edge dissections

Pre-intervention



Post-intervention



# Predictors of DES Early ST, Restenosis, MACE, or DoCE




		IVUS	OCT
	Early ST	Restenosis/MACE	Restenosis/MACE/DoCE
Small MSA or underexpansion in stable lesions	<ul style="list-style-type: none"> <li>•Fujii et al. J Am Coll Cardiol 2005;45:995-8</li> <li>•Okabe et al. Am J Cardiol. 2007;100:615-20</li> </ul>	<ul style="list-style-type: none"> <li>•Sonoda et al. J Am Coll Cardiol 2004;43:1959-63</li> <li>•Hong et al. Eur Heart J 2006;27:1305-10</li> <li>•Doi et al JACC Cardiovasc Interv. 2009;2:1269-75</li> <li>•Fujii et al. Circulation 2004;109:1085-1088</li> <li>•Kang et al. Circ Cardiovasc Interv 2011;4:9-14</li> <li>•Choi et al. Am J Cardiol 2012;109:455-60</li> <li>•Song et al. Catheter Cardiovasc Interv 2014;83:873-8</li> <li>•Kang et al. PLoS One 2015;10(10):e0140421</li> <li>•Hong et al. JAMA 2015;314(:2155-63.</li> <li>•Lee et al. Rev Esp Cardiol 2017;70:88-95</li> <li>•Katagiri et al. Catheter Cardiovasc Interv. 2019 Jan 31. doi: 10.1002/ccd.28105.</li> <li>•Kim et al. EuroIntervention. 2019 Dec 10. pii: EIJ-D-19-00762.</li> <li>•Park et al. JACC Cardiovasc Interv 2020;13:1403-13</li> <li>•Ladwiniec et al. EuroIntervention 2020;16:201-9</li> <li>•Sugane et al. Atherosclerosis, in press</li> </ul>	<ul style="list-style-type: none"> <li>•Prati et al. JACC Cardiovasc Imaging 2015;8:1297-305</li> <li>•Prati et al. Circ Cardiovasc Interv. 2016;9. pii: e003726.</li> <li>•Soeda et al. Circulation 2015;132:1020-9</li> <li>•Matsuo et al. Cathet Cardiovasc Interv 2015;87:E9-14</li> <li>•Prati et al. EuroIntervention 2018;14:e443-e451</li> <li>•Katsura et al. Catheter Cardiovasc Interv 2020: 10.1002/ccd.28871</li> </ul>
Small MLA in ACS/MI lesions	<ul style="list-style-type: none"> <li>•Liu et al. JACC Cardiovasc Interv. 2009;2:428-34</li> <li>•Choi et al. Circ Cardiovasc Interv 2011;4:239-47</li> </ul>		
Edge problems (geographic miss, secondary lesions, large plaque burden, dissections, etc)	<ul style="list-style-type: none"> <li>•Fujii et al. J Am Coll Cardiol 2005;45:995-8</li> <li>•Okabe et al., Am J Cardiol. 2007;100:615-20</li> <li>•Liu et al. JACC Cardiovasc Interv. 2009;2:428-34</li> <li>•Choi et al. Circ Cardiovasc Interv 2011;4:239-47</li> </ul>	<ul style="list-style-type: none"> <li>•Sakurai et al. Am J Cardiol 2005;96:1251-3</li> <li>•Liu et al. Am J Cardiol 2009;103:501-6</li> <li>•Costa et al, Am J Cardiol, 2008;101:1704-11</li> <li>•Kang et al. Am J Cardiol 2013;111:1408-14</li> <li>•Kobayashi et al. Circ Cardiovasc Interv. 2016;9:e003553</li> <li>•Calvert et al. Catheter Cardiovasc Interv 2016;88:340-7</li> <li>•Park et al. JACC Cardiovasc Interv 2020;13:1403-13</li> </ul>	<ul style="list-style-type: none"> <li>•Prati et al. JACC Cardiovasc Imaging 2015;8:1297-305</li> <li>•Prati et al. Circ Cardiovasc Interv. 2016;9. pii: e003726.</li> <li>•Ino et al. Circ Cardiovasc Interv. 2016;9:e004231</li> <li>•Prati et al. EuroIntervention 2018;14:e443-e451</li> <li>•van Zandvoort et al. Circ Cardiovasc Interv. 2020;13:e008685</li> </ul>
Protrusion in ACS/MI Irregular Protrusion	<ul style="list-style-type: none"> <li>•Choi et al. Circ Cardiovasc Interv 2011;4:239-47</li> <li>•Hong et al. Int J Cardiol 2013;168:1674-5</li> </ul>		<ul style="list-style-type: none"> <li>•Prati et al. Circ Cardiovasc Interv. 2016;9. pii: e003726.</li> <li>•Soeda et al. Circulation 2015;132:1020-9</li> </ul>
Stent length (>40mm)		<ul style="list-style-type: none"> <li>•Hong et al. Eur Heart J 2006;27:1305-10</li> </ul>	
Asymmetry/Eccentricity		<ul style="list-style-type: none"> <li>•Suwannasom et al. JACC Cardiovasc Interv 2016;9:1231-42 (not significant at long term follow-up: JACC Cardiovasc Interv 2018;11:1013-5)</li> </ul>	
Acute malapposition			<ul style="list-style-type: none"> <li>•Souteyrand et al. Eur Heart J. 2016;37:1208-16</li> </ul>

Acute  
malapposition is  
detected in 14%  
by IVUS and  
50% by OCT  
after routine  
stenting

	Study	#	IVUS	OCT
Hong et al. Circulation. 2006;113:414-9	AMC	683	7%	
Steinberg et al. JACC Cardiovasc Interv 2010;3:486-94	Combined TAXUS	1200	8%	
Guo et al. Circulation 2010;122:1077-84	HORIZONS-AMI	263	36%	
Kang et al. Circ Cardiovasc Interv 2011;4:562-9.		403	7%	
Van der Hoven et al. JACC Cardiovasc Interv 2008;1:192-201	MISSION-AMI	184	35%	
Bezerra et al. JACC Cardiovasc Interv 2013;6:228-36		26	42%	96%
Kubo et al. JACC Cardiovasc Imaging 2013;6:1095-1104	OPUS-CLASS	100	14%	39%
Im et al. Circ Cardiovasc Interv 2014;7:88-96		356		62%
Kawamori et al. EHJ Cardiovasc Imaging 2013;14:865-75		40		65%
Shimamura et al. EHJ Cardiovasc Imaging 2015;16:23-8		77		100%
Soeda et al. Circulation 2015;132:1020-9		1001		39%
Prati et al. JACC Cardiovasc Imaging 2015;8:1297-305	CLI-OPCI-II	1002		49%
Bernelli et al. Circ J 2016;80:895-905	OCTAVIA	114		72%
Kim et al. J Interv Cardiol 2016;29:216-24		122		48%
Wang et al. J Am Heart Assoc. 2016;5. pii: e004438. doi: 10.1161	ADAPT-DES	168	37%	
Prati et al. Circ Cardiovasc Interv. 2016;9. pii: e003726	CLI-OPCI ACS	2430	13%	
Ali et al. Lancet. 2016;388:2618-28	ILUMIEN III	588		48%
Agarwal et al. Catheter Cardiovasc Interv 2017;90:225-232		304		36%
Lee et al. Circ Cardiovasc Interv. 2018;11:e007192	DETECT-OCT	146	18%	
Ladwiniec et al. Eurointervention 2020;16:201-9	NOBLE	110		75%
<b>Overall</b>		390	45%	
		224	5%	
			<b>14%</b>	<b>50%</b>

# Events related to acute stent malapposition (6426 pts)

	Study		F-U	Acute malapposition	No acute malapposition
Steinberg et al. JACC Cardiovasc Interv 2010;3:486-94	Combined TAXUS	IVUS	9 mos	8.2% MACE	10.7% MACE
Van der Hoeven et al. JACC Cardiovasc Interv 2008;1:192-201	MISSION-AMI	IVUS	9 mos	0% ST	0% ST
Guo et al. Circulation 2010;122:10-77-84	HORIZONS-AMI	IVUS	13 mos	0% ST	0% ST
Soeda et al. Circulation 2015;132:1020-9		OCT	1 yr	4.4% DoCE	4.8% DoCE
Prati et al. JACC Cardiovasc Imaging 2015;8:1297-305	CLI-OPCI-II	OCT	1 yr	13% MACE	10% MACE
Wang et al. J Am Heart Assoc. 2016;5. pii: e004438. doi: 10.1161	ADAPT-DES	IVUS	2 yrs	5.2% MACE (0.65% ST)	4.5% MACE (0.43% ST)
Prati et al. Circ Cardiovasc Interv. 2016;9. pii: e003726.	CLI-OPCI-ACS	OCT	9 mos	12.8% MACE	12.4% MACE
Ladwiniec et al. Eurointervention 2020;16:201-9	NOBLE	IVUS	5 yrs	33% MACCE (8% mortality, 0% ST)	21% MACCE (6% mortality, 1% ST)



# OCT calcium scoring system predicting stent expansion

## Test cohort of 128 pts

	Regression Coefficient	95% CI	P-value	Calcium Score	$\leq 180^\circ$	0
Maximum calcium angle (per $180^\circ$ )	-7.43	-12.6 to -2.21	<0.01	<b>Maximum calcium angle</b>	$\leq 180^\circ$	0
					$>180^\circ$	2
Maximum calcium thickness (per 0.5 mm)	-3.40	-6.35 to -0.45	0.02	<b>Maximum calcium thickness</b>	$\leq 0.5\text{mm}$	0
					$>0.5\text{mm}$	1
Calcium length (per 5 mm)	-3.32	-4.09 to -0.55	0.01	<b>Calcium length</b>	$\leq 5\text{mm}$	0
					$>5\text{mm}$	1

## Validation cohort of 133 pts

Score	0 (n=27)	1 (n=45)	2 (n=34)	3 (n=3)	4 (n=24)	P-value
MSA, $\text{mm}^2$	7.2 (5.4, 9.2)	6.3 (5.2, 8.4)	5.9 (4.8, 8.0)	6.7 (5.8, 7.1)	5.7 (4.4, 7.4)	0.21
Stent expansion at target lesion calcium, %	99 (93, 108)	98 (86, 109)	86 (77, 100)	98 (83, 104)	78 (70, 86)	<0.01
Stent expansion at MSA, %	91 (84, 95)	85 (78, 93)	80 (73, 93)	80 (73, 85)	69 (60, 77)	<0.01

# IVUS calcium score predicting stent expansion (as a continuous variable) in lesions with calcium >270°


## Test cohort of 97 pts


	Regression Coeff	95% CI	P-value	Cut-off	Calcium Score		
Length of calcium >270° (per 5mm)	-5.5	-9.7, -1.2	0.01	5.0	≤5mm	0	
					>5mm	1	
Calcium Nodule	-10.2	-16.3 to -4.2	0.0009		absent	0	
					present	1	
Vessel diameter (per 1mm)	8.6	2.7 to 14.4	0.004	3.5	>3.5mm	0	
					≤3.5mm	1	
Circumferential calcium	-14.3	-25.0 to -3.5	0.009		absent	0	
					present	1	


## Stent underexpansion (<70%) in the validation cohort of 97 pts


	Cut-off	C-statistics	Sensitivity	Specificity	PPV	NPV
Score	≥2	0.85 [0.77, 0.93]	89%	63%	48%	94%


In 67 lesions without angiographically visible calcium, but with a maximum IVUS angle of superficial calcium >270°, there were none with a calcium score of 4 and only 1 with stent underexpansion.
















# OPINION: Randomized trial of IVUS vs OCT-guided DES implantation in ~800 patients

Primary endpoint: Target vessel failure (cardiac death, target vessel related MI, clinically driven TVR)-free survival







# Bayesian network meta-analysis of 31 studies and 17,882 pts comparing clinical outcomes of PCI with BMS and/or DES implantation guided by angiography, IVUS, or OCT



- Angiography (29 studies; 8434 pts), IVUS (17 studies; 7825 pts), OCT (7 studies; 1623 pts)
- Angiography vs IVUS (24 studies; 14295 pts), Angiography vs OCT (4 studies; 2092 pts), IVUS vs OCT (2 studies; 1045 pts), Angiography vs IVUS vs OCT (1 study; 450 pts)

# IVUS and OCT-guided primary PCI in the KAMIR Registry

- KAMIR (Korean AMI Registry) is an online, open-label registry at 20 sites that was established in 2011 with the help of the Korean NIH
- From 11/2011 to 12/2015, 11,731 STEMI pts underwent 1° PCI: 9072 with angio-guidance and 2333 with IVUS and 277 with OCT to optimize stent expansion, apposition, and lesion coverage.



In the propensity-score matched cohort, difference in POCE was mainly driven by reduced all-cause mortality with IVUS (4.9% vs. 7.0%; log-rank p=0.002) and OCT (1.9% vs. 7.0%; log-rank p=0.004). The difference in DOCE was mainly driven by reduced cardiac mortality in IVUS (3.6% vs. 5.2%; log-rank p=0.009) and OCT-guided PCI (1.4 vs. 5.2%; log-rank p=0.014).

# 45 year-old male with CCS class 2 chest pain.

- Coronary risk factors
  - Type 1 diabetes mellitus
  - Hypertension
  - Current smoker
- Past medical history
  - Chronic renal failure on hemodialysis

c/o Myong Hwa Yamamoto and Masahiko Ochiai  
Showa University Northern Yokohama Hospital  
Yokohama, Japan




Calcium Score	
≤5mm	0
>5mm	1
absent	0
present	1
>3.5mm	0
≤3.5mm	1
absent	0
present	1

**Length of calcium >270°**

**Calcium Nodule**


**Vessel diameter**

**Circumferential calcium**



0 — 5mm

— 20mm



Balloon pre-dilation



Promus Premier  
3.0\*38mm@18atm




Balloon post-dilation  
Quantum 4.0mm@24atm



Stent expansion=45%




Two months later





**Standard NC balloon**  
**3.5mm@20atm**

**Drug-coated balloon**  
**3.5mm@20atm**





Another two months later





Pre-dilation  
3.75mm@20atm

Nobori  
3.5\*14mm@16atm



# Another one month later



IVUS

OCT



Stent sizing & optimization	+++	+++
Ruptured plaque and thrombus	+	+++
Left main lesions	+++	+
Aorto-ostial lesions	+++	-
Calcium	++	+++
Chronic total occlusions	+++	-
In-stent restenosis	++	+++
Impaired renal function	+++	-

- 80-90% of your PCI-guidance needs can be addressed with either IVUS or OCT. Pick one and get good at it!
  - In the other 10-20% of cases and depending on your practice, it is important to know which patient, which lesion, and which clinical scenario will be better suited to IVUS vs OCT assessment and/or guidance.

